 |
 |
|
|
| |
Graffinity - fragment based
drug discovery
 Graffinity is the premier partner for fragment
based drug discovery and lead development of small molecule
pharmaceuticals. Graffinity has built a unique approach which includes
chemical microarrays, fragment screening, SPR label-free imaging of
protein-ligand interactions, computational chemistry and lead
discovery. The technology platform offers a new drug discovery paradigm
for the rapid conversion of genomic information into novel, high
quality leads and drug candidates.
Graffinity applies this technology in established high-profile
collaborations with leading Pharma and Biotech companies.
|
|
|
|
|
|
| |
 |
|
Press Releases:
|
 January
26, 2009:
Graffinity and Elan launch Fragment-based Drug Discovery collaboration
 read more
... |
|
October
28, 2008:
Graffinity and AstraZeneca enter into multi-target drug discovery
alliance
read more ... |
|
September
19, 2008:
Graffinity and EMBL awarded € 0.9 million grant from German Government
read more ... |
|
June
3, 2008:
Graffinity and Rigel enter into drug discovery research alliance
read more ... |
|
November
29, 2007:
Graffinity announces multitarget drug discovery research collaboration
with Pfizer
read more ... |
|
February
26, 2007:
Graffinity and Amgen enter into drug discovery research agreement
read more ... |
|
|
|
|
|
|
